Trial Profile
Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena plus a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar disorders
- Focus Therapeutic Use
- Acronyms BD-CAEL
- 11 Sep 2020 Status changed from active, no longer recruiting to completed.
- 30 Apr 2020 Planned End Date changed from 1 Feb 2021 to 31 Dec 2020.
- 30 Apr 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Jul 2020.